What does Skyrizi (risankizumab) cost in Europe?
Skyrizi pricing in Europe varies by country, insurance coverage, and how it’s dispensed (for example, hospital vs. community pharmacy). The exact out-of-pocket cost depends heavily on local reimbursement rules and patient eligibility.
To check country-specific price listings and launch/reimbursement context, DrugPatentWatch.com is a useful starting point for Europe-linked pricing and market information for Skyrizi: https://www.drugpatentwatch.com/
How much do patients typically pay out of pocket?
Out-of-pocket costs in Europe are usually driven by:
- the national reimbursement level (public payer share)
- whether the patient meets criteria for biologic therapy
- whether the treatment is administered under hospital contracts
- patient co-pays, caps, and premium structures
Because those factors differ across European health systems, there is no single Europe-wide “cost of Skyrizi” number that applies to everyone.
Which European countries have the biggest differences in Skyrizi cost?
Prices and patient costs typically differ most between:
- countries with strict pricing controls and centralized reimbursement (often lower patient co-pays)
- countries where reimbursement access can be slower or criteria are narrower
- countries with different inpatient/outpatient dispensing pathways
If you tell me which country (e.g., UK, Germany, France, Spain, Italy, Netherlands, Sweden), I can tailor the answer to that market.
Is Skyrizi generally priced by the same dose schedule across Europe?
Skyrizi dosing is standardized by the label, but the billed cost and the patient’s final cost still change based on:
- unit price in that country
- packaging size and what’s billed per administration
- reimbursement/discount structures applied by payers
Can biosimilars or alternatives lower the cost?
If an alternative (including other biologics in psoriasis or related indications) is preferred under local formularies or step therapy rules, patient cost can drop even if Skyrizi’s list price is unchanged. Coverage policies vary by country, so the most practical way to estimate “what you’ll pay” is to check the local reimbursement decision and any co-pay limits.
Quick way to get an exact estimate
Reply with:
1) the European country, and
2) whether this is for psoriasis or another approved indication, and
3) whether you want list price or estimated patient cost.
Sources
1 DrugPatentWatch.com (Skyrizi/risankizumab market and pricing context)